Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity

v3.23.2
Stockholders’ Equity
 6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Stockholders’ Equity Stockholders’ Equity
Stock-Based Compensation Expense
Stock-based compensation expense, consisting of service-based expense related to the equity incentive plan, including expense from stock options and restricted stock units, and the employee stock purchase plan, as well as expenses related to secondary sales of shares of Company common stock, was classified as follows in the accompanying condensed consolidated statements of operations for each of the periods presented (in thousands):
Three Months Ended June 30, Six Months Ended June 30,
2023 2022 2023 2022
Cost of revenue $ 251  $ 176  $ 464  $ 324 
Sales and marketing 1,219  790  2,183  1,487 
Research and development 1,323  1,078  2,253  1,630 
General and administrative 3,083  2,436  5,489  4,464 
Total $ 5,876  $ 4,480  $ 10,389  $ 7,905 
Equity Incentive Plan
During 2016, the Company adopted the 2015 Equity Incentive Plan (the “2015 EIP”) under which common stock options could be issued for employee awards, and the Company began issuing stock options under this plan in 2016.
In November 2021, in connection with the initial public offering (“IPO”), the Company adopted the 2021 Equity Incentive Plan (the “2021 EIP” and, together with the 2015 EIP, the “EIP”) under which the Company could issue stock options or restricted stock units (“RSUs”) as awards. Upon adoption of the 2021 EIP, the 2015 EIP plan was terminated. All options issued and outstanding or available for issuance under the 2015 EIP were absorbed into the 2021 EIP. Along with the absorbed 2015 EIP options, the Company reserved an additional 9.0 million shares of common stock for future issuance under the 2021 EIP, with scheduled annual increases to the reserve for amounts to be determined by the Board, subject to a maximum amount. In the first quarter of 2023 and 2022, respectively, the board reserved an additional 3.3 million and 3.2 million common shares for future issuance under the 2021 EIP.
In March 2023, the Company adopted the 2022 Inducement Equity Incentive Plan and reserved an additional 7.0 million shares of common stock for future issuance.
Stock-based compensation expense related to the EIP was $5.7 million and $4.4 million for the three months ended June 30, 2023 and 2022, respectively, and $10.1 million and $7.7 million for the six months ended June 30, 2023 and 2022, respectively.
Stock Options
Most options have a four-year vesting schedule with a one-year cliff and are classified as incentive stock options (“ISOs”). Some options have been granted in lieu of bonuses and have expedited two- or three-year vesting schedules. All awards vest based on service conditions.
Options with accelerated vesting clauses, should there be a change in Company control, were 1,666,097 and 3,149,649 as of June 30, 2023 and 2022, respectively.
Unrecognized stock-based compensation expense related to outstanding options as of June 30, 2023 and 2022 was $6.4 million and $21.2 million, respectively. Stock-based compensation expense is recognized on a straight-line basis over the remaining weighted-average vesting periods. As of June 30, 2023 and 2022 the weighted-average vesting periods approximated 1.62 years and 2.42 years, respectively.
Stock option activity was as follows:
Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value
(in thousands)
Outstanding as of December 31, 2022 4,185,876  $ 6.32  5.03 $ 3,470 
Exercisable as of December 31, 2022 3,060,997  $ 6.47  3.87 $ 3,286 
Granted —  $ — 
Exercised (41,175) $ 1.76 
Forfeited and expired (230,775) $ 6.16 
Outstanding as of March 31, 2023 3,913,926  $ 6.38  4.38 $ 3,928 
Exercisable as of March 31, 2023 3,101,573  $ 6.43  3.42 $ 3,744 
Granted —  $ — 
Exercised (308,966) $ 1.77 
Forfeited and expired (221,306) $ 14.38 
Outstanding as of June 30, 2023 3,383,654  $ 6.28  4.68 $ 16,411 
Exercisable as of June 30, 2023 2,698,899  $ 6.28  3.89 $ 13,104 
The aggregate intrinsic value of options exercised was $1.6 million for the three months ended June 30, 2023. The intrinsic value represents the excess of the estimated fair value of the Company's common stock on the date of exercise over the exercise price of each option.
Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award. The fair value of the awards is fixed at grant date and amortized over the remaining service period. The Company uses the Black-Scholes model to estimate the value of its stock options issued under the EIP. Prior to the IPO, the common stock fair values used in the models were based on the most recent 409(a) valuation as of the option grant date. Management reviews option grants and determines whether further valuation adjustments are appropriate based on recent company performance and/or changes in market conditions. The volatility assumed in the estimate was based on publicly traded companies in the same industry and considers the expected term calculated by the Company. The expected term of the options was derived from a simplified method which estimates the term based on an averaging of the vesting period and contractual term of the option grant. The risk-free rate utilized was the average of the five- and seven-year U.S. Treasury yields as the estimated expected term for options approximates 6 years. The Company has no plans to declare dividends in the foreseeable future.
Restricted Stock Units
RSUs granted under the Plan vest and settle upon the satisfaction of a service-based condition. The service based condition for these awards is generally satisfied over three or four years. A total of 171,075 RSUs have a four-year vesting schedule with 25% cliff vesting one year from grant date and the remaining 75% vesting monthly over the remaining three years. A total of 59,362 RSUs issued to non-employee directors have a three-year vesting schedule, with 33% vesting one year from the grant date and the remaining 67% vesting annually over the remaining two years. A total of 146,136 RSUs issued to non-employee directors have a one-year vesting schedule, with 100% vesting on the earlier of one year from the grant date or the annual meeting of stockholders. The remaining RSUs that have been issued have a three-year vesting schedule with 33% vesting one year from grant date and the remaining 67% vesting quarterly over the remaining two years.
As of June 30, 2023, there was $40.2 million of unrecognized stock-based compensation expense related to outstanding RSUs which is expected to be recognized over a weighted-average period of 2.2 years.
Restricted Stock Unit activity was as follows:
Number of Shares Weighted Average Grant Date Fair Value
Outstanding as of December 31, 2022 8,278,361  $ 5.51 
Granted 57,137  $ 5.38 
Vested (586,640) $ 6.43 
Canceled (291,799) $ 5.77 
Outstanding as of March 31, 2023 7,457,059  $ 5.42 
Granted 2,553,295  $ 5.27 
Vested (1,046,426) $ 5.67 
Canceled (149,850) $ 5.68 
Outstanding as of June 30, 2023 8,814,078  $ 5.36 
The total fair value of RSUs that vested during the three and six months ended June 30, 2023, was $6.0 million and $8.8 million, respectively. A portion of these RSUs were net-settled such that the Company withheld shares with a value equivalent to the employees’ obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. During the three and six months ended June 30, 2023, the Company withheld 369,761 and 533,513 shares, respectively, which was based on the value of the RSUs on their respective vesting dates as determined by the Company’s closing stock price. Total payments for the employees’ tax obligations to taxing authorities was $1.9 million for the three months ended June 30, 2023 and $2.7 million for the six months ended June 30, 2023. Prior to 2023, the Company had not net-settled vesting RSUs.
Employee Stock Purchase Plan
In October 2021, the Company adopted the Employee Stock Purchase Plan (“ESPP”) in which eligible employees may contribute up to 50% of their base compensation to purchase shares of common stock at a price equal to 85% of the lower of (1) the fair market value of a share of the Company’s common stock at the beginning of the offering period and (2) the fair market value of a share of the Company’s common stock on the purchase date. No participant may purchase more than 2,500 shares during any offering period. As of June 30, 2023 and December 31, 2022, 2,600,637 and 1,943,246 shares were reserved for issuance, and 299,683 and 165,347 shares, respectively, of common stock had been issued under the ESPP. The number of shares available for issuance under the ESPP may be increased on the first day of each fiscal year by an amount to be determined by the board of directors.
Except for the initial offering period, the 2021 ESPP provides for six-month offering periods beginning February 16 and August 16 of each year, and the last day of each offering period is the purchase date for that period. The initial offering period began on December 1, 2021 and ended on August 15, 2022 and consists of one purchase period, which is the last day of the offering period.
During each of the three months ended June 30, 2023 and 2022, the Company recognized $0.1 million of stock-based compensation expense related to the ESPP, and during the six months ended June 30, 2023 and 2022, the Company recognized $0.3 million and $0.2 million of stock-based compensation expense related to the ESPP, respectively. As of June 30, 2023 and December 31, 2022, $0.7 million and $0.6 million in accrued ESPP employee payroll contributions are included within accrued liabilities on the consolidated balance sheets, respectively. As of June 30, 2023, total unrecognized compensation costs related to the ESPP was $0.1 million, which will be amortized over the remaining offering period through August 15, 2023.
Repurchase of Common Shares
No share repurchases took place during the three and six months ended June 30, 2023 and 2022.